TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients

Status Recruiting

Clinical Trial Summary

Hematopoietic stem cell transplant (HSCT) is an effective but toxic therapy and pulmonary morbidity affects as many as 25% of children receiving transplant. Early pulmonary injury includes diffuse alveolar hemorrhage (DAH), thrombotic microangiopathy (TMA) interstitial pneumonitis (IPS) and infection, while later, bronchiolitis obliterans is a complication of chronic GVHD associated with severe morbidity and mortality. Improved diagnosis and treatment of pulmonary complications are urgently needed as survival after HSCT improves, and as HSCT is increasingly used for non-malignant disorders such as sickle cell disease. Currently, there are large and important gaps in the investigator's knowledge regarding incidence, etiology and optimal treatment of pulmonary complications. Moreover, young children unable to perform spirometry are often diagnosed late, and strategies for monitoring therapeutic response are limited. This is a prospective multi-institutional cohort study in pediatric patients undergoing allogeneic (alloHSCT) or autologous hematopoietic stem cell transplantation (autoHSCT). Assembly of a large prospective uniformly screened cohort of children receiving HSCT, together with collection of biological samples, will be an effective strategy to identify mechanisms of lung injury, test novel diagnostic strategies for earlier diagnosis, and novel treatments to reduce morbidity and mortality from lung injury after transplant.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Bronchiolitis
Bronchiolitis Obliterans
Bronchiolitis Obliterans Syndrome
Diffuse Alveolar Hemorrhage
Hematopoietic Stem Cell Transplant (HSCT)
Hemorrhage
Interstitial Pneumonitis
Lung Diseases, Interstitial
Lung Injury
Pneumonia
Thrombotic Microangiopathies

Clinical Trial Details

NCT number	NCT04098445
Study type	Observational
Source	Children's Hospital Medical Center, Cincinnati
Contact	Stephanie Edwards, BSN, RN
Phone	513-636-9292
Email	StephanieL.Edwards@cchmc.org
Status	Recruiting
Phase
Start date	September 8, 2021
Completion date	September 2036

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03603899` - Hp129 Xenon Imaging and BOS in Lung Transplantation	Phase 1/Phase 2
Completed	`NCT02441413` - Transplant Optimization Using Functional Imaging (TROFI)	N/A
Recruiting	`NCT02543073` - MSC for Treatment of Interstitial Lung Disease After Allo-HSCT	Phase 1/Phase 2
Terminated	`NCT01432080` - Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant	Phase 2
Recruiting	`NCT00163696` - Multi Breath Nitrogen Washout (MBNW) as a Measure of Small Airway Function in Patients With Respiratory Disease	N/A
Completed	`NCT00029328` - Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation	Phase 1/Phase 2
Terminated	`NCT01163786` - A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD	Phase 2
Recruiting	`NCT02627833` - Lung Function, LCI, Bronchial Inflammation and Epigenetics of Patients With BO	N/A
Completed	`NCT01212406` - Vitamin D in Bronchiolitis Obliterans Syndrome	Phase 4
Completed	`NCT01211509` - Montelukast in Bronchiolitis Obliterans Syndrome	Phase 4
Completed	`NCT00701922` - Surveillance Study of Viral Infections Following Lung Transplantation	N/A
Completed	`NCT00141726` - Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant	Phase 2
Recruiting	`NCT05922761` - BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)	Phase 2
Recruiting	`NCT05881538` - High Intensity Intervallic Training in Children With Bronchiolitis Obliterans	N/A
Terminated	`NCT04655508` - Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 ≥10% From Pre Transplantation	Phase 3
Withdrawn	`NCT02109237` - Sleep Disorders in Bronchiolitis Obliterans Syndrome 2&3	N/A
Completed	`NCT01327248` - Clinical Status and Bronchial Inflammation in Patients With Bronchiolitis Obliterans	N/A
Recruiting	`NCT05932316` - Evaluating Bronchodilator Response in Patients With Bronchiectasis	N/A
Active, not recruiting	`NCT03656926` - Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2)	Phase 3
Completed	`NCT01206309` - Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation	N/A